Plus Therapeutics (PSTV)
(Delayed Data from NSDQ)
$1.37 USD
+0.07 (5.38%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.39 +0.02 (1.46%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.37 USD
+0.07 (5.38%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.39 +0.02 (1.46%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Zacks News
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
DURECT (DRRX) delivered earnings and revenue surprises of 25% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of 10.26% and 4.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Plus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Plus (PSTV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of 0% and 68.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of -6.67% and 88.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?